|
Investigation results: manufacturing and quality control data: the progav® 2.0 shunt system was manufactured by a qualified employee in july 2021.Deviations during assembly did not occur.The system was sterilized by miethke and released for shipment after final inspection.The progav® 2.0 shunt system includes a progav® 2.0 adjustable pressure valve with a normal pressure range of 0 to 20 cmh2o and a shuntassistant® 2.0 fixed pressure valve with a fixed pressure range of 25 cmh2o.The shunt system was inspected as article fx571t.All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specifications.Visual inspection: no significant deformations or damage of the valves were detected during the visual inspection.Permeability test: a permeability test has shown that both valves are permeable.Adjustment test: the progav® 2.0 was tested and is adjustable to all specified pressures.Klick force and brake function test: the click force of the progav® 2.0 was within the permissible specification and the function of the brake could be tested without any problems.Finally, we have dismantled the valves.Inside both valves we have found significant build-up of substances (likely protein).Based on our investigation, we are unable to substantiate the clinical claim of occlusion.At the time of our investigation, the valves were shown to be permeable.However, it is possible that the deposits observed inside the valve could have caused the malfunction in the past.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hc-therapy by shunt implants.We can exclude a defect at the time of release.The shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required from our point of view.
|